Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer.
Atrophic vaginitis
breast cancer
patient-reported outcomes
topical estrogen
Journal
Proceedings (Baylor University. Medical Center)
ISSN: 0899-8280
Titre abrégé: Proc (Bayl Univ Med Cent)
Pays: United States
ID NLM: 9302033
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
13
12
2019
revised:
24
02
2020
accepted:
06
03
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
epublish
Résumé
The aim of this retrospective study was to assess the efficacy of topical hormonal therapy (THT) to relieve vaginal symptoms resulting from antihormonal therapy in women with hormone receptor-positive breast cancer. A total of 74 breast cancer patients who received THT for vaginal complaints were retrospectively identified and statistically matched with 74 control breast cancer patients with vaginal complaints with no documented use of THT. Symptom scores were recorded from the center's proprietary patient-reported outcomes database, Patient Care Monitor (ConcertoHealthAI, Boston). A baseline score was noted at the initiation of antihormonal therapy and was followed at 6 and 12 months. The median differences between baseline, 6-month, and 12-month scores were analyzed. Repeated measures analysis of variance assessed the impact of topical hormonal replacement. There was no statistically significant difference in score change between the two groups at 6 and 12 months. In the active THT group, there were no statistically significant differences in vaginal complaints or sexual problems over time: {
Identifiants
pubmed: 32675948
doi: 10.1080/08998280.2020.1744059
pii: 1744059
pmc: PMC7340418
doi:
Types de publication
Journal Article
Langues
eng
Pagination
331-335Informations de copyright
Copyright © 2020 Baylor University Medical Center.
Références
Menopause. 2013 Sep;20(9):888-902; quiz 903-4
pubmed: 23985562
In Vivo. 1996 Nov-Dec;10(6):597-600
pubmed: 8986469
Maturitas. 2006 Sep 20;55(2):103-15
pubmed: 16815651
Eur J Cancer. 2005 Nov;41(17):2673-81
pubmed: 16239103
J Oncol Pract. 2012 May;8(3):144-8
pubmed: 22942807
Climacteric. 2003 Mar;6(1):45-52
pubmed: 12725664
J Sex Med. 2009 Aug;6(8):2133-42
pubmed: 19493278
Am J Obstet Gynecol. 2011 Jan;204(1):26.e1-7
pubmed: 20950790
Menopause. 2014 Mar;21(3):267-74
pubmed: 23860358
JAMA Oncol. 2017 Mar 1;3(3):313-319
pubmed: 27832260
Ann Oncol. 2006 Apr;17(4):584-7
pubmed: 16443612
CMAJ. 2002 Apr 16;166(8):1017-22
pubmed: 12002977
Menopause. 2017 Jul;24(7):728-753
pubmed: 28650869
Lancet. 2004 Feb 7;363(9407):453-5
pubmed: 14962527
Breast Cancer Res Treat. 2015 Jul;152(1):1-8
pubmed: 26003182
Ginekol Pol. 2012 Oct;83(10):772-7
pubmed: 23383564
Cochrane Database Syst Rev. 2016 Aug 31;(8):CD001500
pubmed: 27577677
Breast Cancer Res Treat. 2012 Sep;135(2):603-9
pubmed: 22903687
Obstet Gynecol. 2016 Mar;127(3):e93-6
pubmed: 26901334
Oncologist. 2008 Mar;13(3):222-31
pubmed: 18378532
Am J Clin Oncol. 2018 Mar;41(3):313-315
pubmed: 26840041
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD001500
pubmed: 17054136
Dermatol Ther. 2010 Sep-Oct;23(5):514-22
pubmed: 20868405
CA Cancer J Clin. 2016 Jan-Feb;66(1):43-73
pubmed: 26641959
Climacteric. 2011 Jun;14(3):339-44
pubmed: 21226657
Breast J. 2011 Jul-Aug;17(4):403-8
pubmed: 21645165
J Clin Oncol. 2005 Nov 1;23(31):7804-10
pubmed: 16219936
J Natl Cancer Inst. 2005 Apr 6;97(7):533-5
pubmed: 15812079